Skip to content

Survey of Tranexamic acid affect on reduction of secondary hemorrhage in the traumatic hyphema

Survey of Tranexamic acid affect on reduction of secondary hemorrhage in the traumatic hyphema

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201106016675N1
Enrollment
54
Registered
2011-07-19
Start date
2006-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blunt eye trauma. Traumatic hyphema

Interventions

Intervention 1: Twenty eight patients in intervention group received 25 mg/kg per day oral tranexamic acid (TA) into 3 doses for 5 days and received routine treatment including: betamethasone, hematro
Treatment - Drugs
Twenty eight patients in intervention group received 25 mg/kg per day oral tranexamic acid (TA) into 3 doses for 5 days and received routine treatment including: betamethasone, hematropine, timolol, a
Twenty six patients in control group received routine treatment including: betamethasone, hematropine, timolol, acetazolamide and chloramphenicol without tranexamic acid (TA).

Sponsors

Vice chancellor for research, Ardebil University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Exclusion criteria including history of eye surgery, Glaucoma , Leukemia , Diabetes Mellitus , Coagulopathy, Rheumatoid Arthritis, Optic nerve atrophy ,Uveit, antifibrinolytic and topical steroid intake history

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Rebleeding. Timepoint: 3-5 day after bleeding the rebleeding and increase of bleeding were cheked in two group. Method of measurement: Slit lamp examination and record in chek list.

Secondary

MeasureTime frame
Visual aquity. Timepoint: 3-5 day after bleeding visual aquity were cheked in two group. Method of measurement: Snellen chart , Count finger, Light perception.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Rahim Maasumi

Ardebil University Medical Science

r.maasoumi@arums.ac.ir+98 45 1551 0052

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026